KoppeloKLKaplanB. Management of gastroesophageal reflux disease. J Am Pharm Assoc (Wash)1996;NS36(suppl): 16–26.
2.
KeyserMSCrawleyJAGoldbergGAShawMM. Gastroesophageal reflux disease in a managed care setting: Professional, facility and pharmacy charges. J Managed Care Pharm1998;4: 64–70.
3.
MossnerJHolscherAHHerzRSchneidersA. A double blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial. Aliment Pharmacol Ther1995;9: 321–6.
4.
CorinaldesiRValentiniMBelaicheJColinRGeldofHMaierCPantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicenter study. Aliment Pharmacol Ther1995;9:667–71.
5.
HatlebakkJGBerstadACarlingLSvedbergLEUngePEkstromPLansoprazole versus omeprazole in the short term treatment of reflux oesophagitis. Scand J Gastroenterol1993;28:224–8.
6.
MeeASRowleyJL. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther1995;10: 757–63.
7.
Astra Merck 1996 Corporate Report. Wayne, PA: Corporate Relations at Astra Merck, July 1997.
EgglestonAWHuijhebaertSDuboisDHaycoxA. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: A clinical database analysis. Gut1998;49: 13–6.
10.
Klinkenberg-KnolECFestenHPMeuwissenGM. Pharmacological management of gastro-oesophageal reflux disease. Drugs1995;49: 695–710.
11.
BankSMaglerDGreenburgRBlumsteinM. Alternate day omeprazole maintenance therapy in H2RA resistant esophagitis — clinical, gastrin & ECL effects for up to three years (abstract). Gastroenterol1992;102:A35.
12.
BankSGreenburgRBlumsteinMMagierDSchulmanNBriganteL. “Spaced” omeprazole dosing in maintenance therapy of H2RA resistant reflux esophagitis — results from 6–48 months (abstract). Gastroenterol1993;104:A38.
13.
BankS. Daily or intermittent omeprazole requirements in the long-term treatment of erosive esophagitis: Results after 2–8 years of continuous therapy (abstract). Gastroenterol1997;112:A64.
14.
MantidesAKioulanisJNastosHStefanidesGDimitracopoulosATzovarasGMaintenance treatment of severely complicated reflux oesophagitis with low dose of omeprazole (abstract). Gut1994;A173.
15.
KurucarCSontagSJSchnellT. Can we predict which patients with severe gastroesophageal reflux will tolerate alternate day therapy with omeprazole (abstract)? Gastroenterol1996;110:A165.
16.
MehtaVGopalswamyNBardeC. Gastroesophageal reflux on daily vs alternate day omeprazole (abstract). Gastroenterol1994;106:A136.
17.
LadasSDTassiosPSRaptisSA. Alternate day omeprazole maintenance therapy for grade 2–3 reflux esophagitis (abstract). Gastroenterol1997;112:A189.
18.
LadasSDTassiosPSRaptisSA. Criteria for alternate day omeprazole maintenance therapy in patients with grade 2–3 reflux esophagitis (abstract). Gastroenterol1997;112:A189.
19.
LindTHavelundTCarlssonRErikssonGGliseHJunghardOThe effect of omeprazole 20 mg and 10 mg daily on heartburn in patients with endoscopy negative reflux disease treated on an on-demand basis (abstract). Gastroenterol1996;110:A178.
20.
HouckePhForestierSGlofdfainDGuyotPhHelbertTLaurentJ15 mg lansoprazole or 30 mg lansoprazole every other day in the long term treatment of erosive reflux esophagitis (abstract). Gut1997;41 (suppl 3):A202.
21.
RoseveareCGoggonPPatelPSimmonsNKimbleJElliotJAlternate day and prn lansoprazole in the maintenance treatment of oesophagitis (abstract). Gut1998;42 (suppl 1):A86.
